Prostate secretory protein (PSP94) suppresses the growth of androgen- independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis

Prostate

Volumn 38, Issue 2, 1999, Pages 118-125

  Garde, Seema V ^a   Basrur, Vathsala S ^a   Li, Li ^b   Finkelman, Malcolm A ^a   Krishan, Awtar ^c   Wellham, Larry ^c   Ben Josef, Edgar ^d,e   Haddad, Maher ^d   Taylor, John D ^d   Porter, Arthur T ^d,e   Tang, Dean G ^b,d,e,f  

^a Procyon Biopharma Inc   (Canada)

^b Biomide Corporation   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e KARMANOS CANCER INSTITUTE   (United States)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Clonogenecity; Prostate cancer; PSP94

Indexed keywords

ANDROGEN; DNA FRAGMENT; PROSTATE PROTEIN; SECRETORY PROTEIN;

ADOLESCENT; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; ELECTRON MICROSCOPY; FLUORESCENCE MICROSCOPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT;

ANDROGENS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CLONE CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASMS, HORMONE-DEPENDENT; PEPTIDES; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; RATS; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0032941245     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990201)38:2<118::AID-PROS5>3.0.CO;2-G     Document Type: Article

References (17)

1. Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 1997;32:284-293.
2. Tremblay J, Frenette G, Tremblay RR, Dupont A, Thabet M, Dube JY. Excretion of three major prostatic secretory proteins in the urine of normal men and patients with benign prostatic hypertrophy or prostate cancer. Prostate 1987;10:235-243.
3. Teni TR, Sheth AR, Kamath MR, Sheth N. Serum and urinary inhibin-like peptide in benign prostatic hyperplasia and carcinoma of prostate. Cancer Lett 1988;43:9-14.
4. Huang C-L, Brassil D, Rozzell M, Schellhammer PF, Wright GL Jr. Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma. Prostate 1993;23:201-211.
5. Garde SV, Sheth AR, Porter AT, Pienta KJ. A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. Cancer Lett 1993; 70:159-166.
6. Garde SV, Sheth AR, Venkatesan VM, Panchal CJ, Porter AT, Grignon DJ. Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP). Cancer Lett 1994;78:11-17.
7. Hyakutake H, Sakai H, Yogi Y, Tsuda R, Minami Y, Yushita Y, Kanetake H, Nakazono I, Saito Y. Beta-microseminoprotein immunoreactivity as a new prognostic indicator of prostatic carcinoma. Prostate 1993;22:347-355.
8. Garde SV, Sheth AR, Porter AT, Pienta KJ. Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo. Prostate 1993;22:225-233.
9. Lokeshwar BL, Hurkadli KS, Sheth AR, Block NL. Human prostatic inhibin suppresses tumor growth and inhibits clonogenic survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor. Cancer Res 1993;53:4855-4859.
10. Baijal-Gupta M, Fraser JE, Clarke MW, Xuan JW, Finkelman MA. A new scalable purification procedure for prostatic secretory protein (PSP94) from human seminal plasma. Protein Expression Purification 1996;8:483-488.
11. Schwartz LM, Osborne BA. Cell death. San Diego: Academic Press; 1995.
12. Tang DG, Chen YQ, Honn KV. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci USA 1996;93:5241-5246.
13. Tang DG, Honn KV. Apoptosis of W256 carcinosarcoma cells of the monocytoid origin induced by NDGA involves lipid peroxidation and depletion of GSH: role of 12-lipoxygenase in regulating tumor cell survival. J Cell Physiol 1997;172:155-170.
14. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995;92:4507-4511.
15. Miyashita T, Krajewski S, Krejewski M, Wang HG, Lin HK, Lieberman DA, Hoffman B, Reed JC. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-1805.
16. Phadke M, Vijayalakshmi S, Sheth AR. Evidence for the presence of specific receptors for inhibin in human prostate. Indian J Exp Biol 1982;20:419-420.
17. Yang J-P, Baijal-Gupta M, Garde SV, Fraser JE, Finkelman MA, Clarke MW. Identification of binding proteins for PSP94 in human prostate adenocarcinoma cell lines LNCaP and PC-3. Prostate 1998;35:11-17.